Difference between revisions of "Capecitabine (Xeloda)"
m |
|||
| Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/xeloda-capecitabine-342211 Medscape], [http://www.utdol.com/online/content | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/xeloda-capecitabine-342211 Medscape], [http://www.utdol.com/online/content | ||
/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | /search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 31: | Line 21: | ||
[[Category:Colon cancer medications]] | [[Category:Colon cancer medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Gastric cancer medications]] | ||
[[Category:Hepatobiliary cancer medications]] | [[Category:Hepatobiliary cancer medications]] | ||
| + | [[Category:Neuroendocrine tumor medications]] | ||
[[Category:Pancreatic cancer medications]] | [[Category:Pancreatic cancer medications]] | ||
[[Category:Rectal cancer medications]] | [[Category:Rectal cancer medications]] | ||
Revision as of 17:29, 11 June 2014
General information
Class/mechanism: Pyrimidine analog, antimetabolite, inhibitor of thymidylate synthase. Converted in vivo to fluorouracil (5-FU), which is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP).[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, [http://www.utdol.com/online/content /search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.[1]
Patient drug information
- Capecitabine (Xeloda) package insert pages 34-37[1]
- Capecitabine (Xeloda) patient drug information (Chemocare)[4]
- Capecitabine (Xeloda) patient drug information (UpToDate)[5]